FibroGen Inc - Company Profile
Powered by 
All the data and insights you need on FibroGen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date FibroGen Inc Strategy Report
- Understand FibroGen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF) and duchenne muscular dystrophy (DMD). The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
409 Illinois Street, San Francisco, California, 94158
Website
www.fibrogen.com
Telephone
1 415 9781200
No of Employees
486
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FGEN (NASD)
Revenue (2022)
$147.8M
5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
3.2%
(2022 vs 2021)
Market Cap*
$125.4M
Net Profit Margin (2022)
XYZ
7.8%
(2022 vs 2021)
* As of and is in US$
FibroGen Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Roxadustat: |
| Anemia is associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company and AstraZeneca entered into an agreement to terminate the collaboration agreement for roxadustat in the US and other AstraZeneca territories. |
| 2023 | Contracts/Agreements | In May, the company along with Fortis Therapeutics signed an exclusive license with Fortis Therapeutics for FOR46. |
| 2022 | Others | In June, the company announced the completion of patient enrollment in LELANTOS-2, a phase 3 clinical study of Pamrevlumab in Duchenne muscular dystrophy. |
Competitor Comparison
| Key Parameters | FibroGen Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Pfizer Inc | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
| City | San Francisco | New Brunswick | Basel | New York | Leverkusen |
| State/Province | California | New Jersey | - | New York | Nordrhein-Westfalen |
| No. of Employees | 486 | 131,900 | 103,605 | 88,000 | 99,723 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James A. Schoeneck | Chairman | Executive Board | 2020 | 65 |
| Thane Wettig | Director; Chief Executive Officer | Executive Board | 2023 | 58 |
| Juan Graham | Chief Financial Officer | Senior Management | 2021 | 47 |
| Michael D. Lowenstein | Chief Legal Officer | Senior Management | - | - |
| Tricia Stewart | Chief People Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward